Alnylam and PBL Sign Licence Agreement for Baulcombe & Hamilton RNAi patent
“We are pleased to expand our leading IP estate with a license to the Baulcombe patent,” said Laurence Reid, Ph.D., Senior Vice President and Chief Business Officer of Alnylam. “Alnylam continues to leverage its patent estate for the advancement of innovative medicines to patients and to enable the entire RNAi therapeutics field, with over 30 license agreements formed to date.”
U.S. Patent No. 8,097,710 issued in January 2012, and is the most recently issued patent in PBL’s IP estate in short RNAs derived from the seminal work of Prof David Baulcombe and Dr Andrew Hamilton, at The Sainsbury Laboratory (Norwich, UK).
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.